Effect of Glepaglutide, a Long-Acting Glucagon-Like Peptide-2 Analog, on Gastrointestinal Transit Time and Motility in Patients With Short Bowel Syndrome: Findings From a Randomized Trial.
Mark Krogh HvistendahlRahim Mohammad NaimiLotte Hahn EnevoldsenJan Lysgaard MadsenStefan FuglsangPalle Bekker JeppesenPublished in: JPEN. Journal of parenteral and enteral nutrition (2020)
The prolonged GI transit after glepaglutide treatment, along with demonstrated positive effects on intestinal mucosal growth and potential effects on GI hypersecretions, is believed to contribute to the observed beneficial effects on fecal output (primary endpoint) and associated improvement in intestinal absorption.